Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.65 |
| ▸ | CDK9 | P50750 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 16/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.52 |
| ▸ | CCNK | O75909 | 1/20 | 0.52 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 9/20 | 0.48 |
| ▸ | CCND1 | P24385 | 9/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.48 |
| ▸ | CDK7 | P50613 | 9/20 | 0.48 |
| ▸ | CCNH | P51946 | 9/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484470 | 0.85 | CDK1 (0.64) | CDK2KDM4ENPC1MAPTTDP1 | |
| SCHEMBL3851604 | 0.81 | TDP1 (0.78) | CDK2KDM4ENPC1MAPTTDP1 | |
| SCHEMBL3302791 | 0.81 | CDK2 (0.63) | CDK2CDK9KDM4ENPC1MAPT | |
| SCHEMBL3300764 | 0.80 | CDK2 (0.65) | CDK2CDK9KDM4ENPC1MAPT | |
| SCHEMBL3295958 | 0.80 | CDK2 (0.68) | CDK2CDK9KDM4ENPC1MAPT | |
| SCHEMBL3299528 | 0.79 | CDK2 (0.66) | CDK2CDK9KDM4ENPC1MAPT | |
| SCHEMBL3301216 | 0.79 | CDK2 (1.00) | CDK2CDK9CDK1CDK5CDK4 | |
| SCHEMBL3295975 | 0.78 | CDK2 (0.66) | CDK2CDK9KDM4ENPC1MAPT | |
| SCHEMBL3298667 | 0.78 | CDK1 (0.63) | CDK2CDK9KDM4ENPC1MAPT | |
| SCHEMBL3299543 | 0.77 | CDK2 (0.70) | CDK2CDK9KDM4ENPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592581-B2 | Trisubstituted purine derivatives | CYCLACEL LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| CN-101679434-B | 2, 6, 9-substituted purine derivatives having anti proliferative properties | CYCLACEL LTD | 2013-09-25 | — | — | CN | disclosed |
| EP-2139893-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | CYCLACEL LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| CN-101679434-A | Has 2,6 of anti proliferative properties, the purine derivative that 9-replaces | CYCLACEL LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2139893-A2 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | Cyclacel Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122767-A2 | 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122767-A2 | 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093769-A1 | COMPOUNDS | CCR9, NPY1R, BCL9 | CDK2 1751/4885CDK9 57/4885KDM4E 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.